Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal adds vaccine candidates for respiratory syncytial virus and human metapneumovirus to the French pharmaceutical group ...

Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.

Vermont has the second lowest state fatality rate in the US (148.4 per 100K; Hawaii 113.7/100K). Mississippi (466/100K) and ...

The Centers for Disease Control and Prevention said human metapneumovirus – also known as HMPV – filled intensive care units with children and seniors this spring.

No, there’s been a surge of the human metapneumovirus (HMPV). In fact, in mid-March, at the height of the surge, over 19% of all respiratory secretion specimens polymerase chain reaction ...

Maybe it was really a quadruple-demic. A little known and underappreciated virus called human metapneumovirus spiked in the US this spring just after RSV, influenza and Covid-19 died down.